

- 151 [8,753,622](#) **T** [Seneca valley virus based compositions and methods for treating disease](#)
- 152 [8,729,058](#) **T** [Methods and compositions for treating and preventing viral infections](#)
- 153 [8,709,791](#) **T** [Detection of bioagents using a shear horizontal surface acoustic wave biosensor](#)
- 154 [8,685,323](#) **T** [Virus/nanowire encapsulation within polymer microgels for 2D and 3D devices for energy and electronics](#)
- 155 [8,673,319](#) **T** [Chimpanzee adenovirus vaccine carriers](#)
- 156 [8,663,951](#) **T** [Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system](#)
- 157 [8,623,416](#) **T** [Formulations comprising aminosterols](#)
- 158 [8,507,455](#) **T** [Folate conjugates](#)
- 159 [8,486,420](#) **T** [Live virus vaccines](#)
- 160 [8,481,270](#) **T** [Method for chromogenic detection of two or more target molecules in a single sample](#)
- 161 [8,470,611](#) **T** [Biologically self-assembled nanotubes](#)
- 162 [8,426,377](#) **T** [iRNA agents with biocleavable tethers](#)
- 163 [8,420,798](#) **T** [Method for producing nucleic acid probes](#)
- 164 [8,420,620](#) **T** [Induced internalization of surface receptors](#)
- 165 [8,380,442](#) **T** [Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby](#)
- 166 [8,367,643](#) **T** [Surfactant lipids, compositions thereof and uses thereof](#)
- 167 [8,344,125](#) **T** [Modified iRNA agents](#)
- 168 [8,334,373](#) **T** [Nuclease resistant double-stranded ribonucleic acid](#)
- 169 [8,303,966](#) **T** [Immunogenic substances comprising a polyinosinic acid--polycytidilic acid based adjuvant](#)
- 170 [8,298,760](#) **T** [Secondary structure defining database and methods for determining identity and geographic origin of an unknown bioagent thereby](#)
- 171 [8,293,500](#) **T** [Methods for identifying polypeptide targets and uses thereof for treating immunological diseases](#)
- 172 [8,273,868](#) **T** [Compositions and methods for inhibiting viral replication](#)
- 173 [8,265,878](#) **T** [Method for rapid detection and identification of bioagents](#)
- 174 [8,258,159](#) **T** [Inhibitors of the .alpha.2.beta.1/GPIa-IIa integrin](#)

- 175 [8,217,163](#) **T** [Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas](#)
- 176 [8,216,834](#) **T** [Chimpanzee adenovirus vaccine carriers](#)
- 177 [8,214,154](#) **T** [Systems for rapid identification of pathogens in humans and animals](#)
- 178 [8,207,209](#) **T** [Methods of inhibiting viral infection](#)
- 179 [8,183,025](#) **T** [Solenopsis invicta virus](#)
- 180 [8,110,672](#) **T** [Promoter engineering and genetic control](#)
- 181 [8,106,173](#) **T** [Stabilized immune modulatory RNA \(SIMRA\) compounds for TLR7 and TLR8](#)
- 182 [8,076,068](#) **T** [Method for determining immunostimulatory activity of RNA oligonucleotides](#)
- 183 [8,073,627](#) **T** [System for identification of pathogens](#)
- 184 [8,071,309](#) **T** [Methods for rapid identification of pathogens in humans and animals](#)
- 185 [8,057,993](#) **T** [Methods for identification of coronaviruses](#)
- 186 [8,048,630](#) **T** [Methods and agents for detecting Parechovirus](#)
- 187 [8,039,606](#) **T** [Seneca Valley virus based compositions and methods for treating disease](#)
- 188 [8,034,921](#) **T** [iRNA agents targeting CCR5 expressing cells and uses thereof](#)
- 189 [8,017,762](#) **T** [Modified iRNA agents](#)
- 190 [8,017,743](#) **T** [Method for rapid detection and identification of bioagents](#)
- 191 [8,017,358](#) **T** [Method for rapid detection and identification of bioagents](#)
- 192 [8,017,322](#) **T** [Method for rapid detection and identification of bioagents](#)
- 193 [8,003,619](#) **T** [Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide](#)
- 194 [7,964,708](#) **T** [Anti-TSG101 antibodies and their uses for treatment of viral infections](#)
- 195 [7,928,217](#) **T** [Nuclease resistant double-stranded ribonucleic acid](#)
- 196 [7,928,113](#) **T** [Integrin-binding small molecules](#)
- 197 [7,919,302](#) **T** [Solenopsis invicta virus](#)
- 198 [7,910,609](#) **T** [Inhibitors of integrin alpha2beta1 with modified urea moiety](#)
- 199 [7,862,829](#) **T** [Viral adjuvants](#)
- 200 [7,846,655](#) **T** [Compositions and methods for detecting a non plus-stranded RNA virus](#)

- 201 [7,822,782](#) **T** [Application package to automatically identify some single stranded RNA viruses from characteristic residues of capsid protein or nucleotide sequences](#)
- 202 [7,803,765](#) **T** [Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom](#)
- 203 [7,803,525](#) **T** [Detection method for Ljungan virus](#)
- 204 [7,786,290](#) **T** [Double-stranded ribonucleic acid with increased effectiveness in an organism](#)
- 205 [7,781,162](#) **T** [Methods for rapid identification of pathogens in humans and animals](#)
- 206 [7,777,022](#) **T** [Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof](#)
- 207 [7,756,644](#) **T** [System and method for automated selection of T-cell epitopes](#)
- 208 [7,745,418](#) **T** [Compositions and methods for inhibiting viral replication](#)
- 209 [7,741,036](#) **T** [Method for rapid detection and identification of bioagents](#)
- 210 [7,723,509](#) **T** [IRNA agents with biocleavable tethers](#)
- 211 [7,718,354](#) **T** [Methods for rapid identification of pathogens in humans and animals](#)
- 212 [7,696,406](#) **T** [Expression of a recombinant transgene](#)
- 213 [7,638,318](#) **T** [Seneca Valley virus based compositions and methods for treating disease](#)
- 214 [7,547,804](#) **T** [Compounds, compositions, and methods employing same](#)
- 215 [7,442,380](#) **T** [Treatment of diseases caused by viral infection](#)
- 216 [7,435,539](#) **T** [Typing of human enteroviruses](#)
- 217 [7,371,850](#) **T** [Method and composition for reducing expression of ROCK-II](#)
- 218 [7,348,314](#) **T** [Compositions and methods for inhibiting viral replication](#)
- 219 [7,282,599](#) **T** [Dithiocarbamate antiviral agents and methods of using same](#)
- 220 [7,217,510](#) **T** [Methods for providing bacterial bioagent characterizing information](#)
- 221 [7,129,042](#) **T** [Compositions and methods for detecting severe acute respiratory syndrome coronavirus](#)
- 222 [7,108,974](#) **T** [Method for rapid detection and identification of bioagents](#)
- 223 [6,927,031](#) **T** [Methods for identifying polypeptide factors interacting with RNA](#)
- 224 [6,846,621](#) **T** [Typing of human enteroviruses](#)
- 225 [6,555,523](#) **T** [Use of cirsiol and derivatives to treat infections](#)

226 [6,194,141](#)  [Inhibition of picornavirus genome replication by interference with VPg-nucleotidylation and elongation](#)